Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02525510
Other study ID # 029669
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 26, 2017
Est. completion date June 1, 2022

Study information

Verified date June 2022
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To protect kidney function during the transplantation process by comparing mild hypothermia in the deceased organ donor before organs are recovered and pulsatile perfusion of the kidney after recovery and prior to transplantation.


Description:

BACKGROUND: In the initial Mild Hypothermia Randomized Control Trial (RCT), in collaboration with the Organ Procurement and Transplant (OPTN) Region 5 Donor Management Goals (DMG) Workgroup and Web Portal, the research team was able to conduct a multi-center RCT examining the benefits of mild hypothermia in donors after neurologic determination of death (DNDDs) on the outcomes of kidney transplantation. The trial was stopped early by the Data and Safety Monitoring Board (DSMB) due to a significant positive benefit to kidney transplant recipients, including a 38% reduction in the odds of delayed graft function (DGF, the primary outcome measure of the trial). The results of this study have been published in the New England Journal of Medicine (July 2015). This research offers a zero-cost intervention that can substantially increase transplant success as well as the pool of potential donors. To expand upon the success of the hypothermia study, the team is conducting a new RCT to test whether hypothermia is as effective as machine perfusion (MP) of kidneys from DNDDs. In an RCT conducted by the Eurotransplant International Foundation in 2009 (Moers et al. NEJM), the protective effect of MP (OR = 0.57) was similar to that found in the Mild Hypothermia Trial (OR = 0.62). However, the cost of MP can be very significant for organ procurement organizations (OPOs) and transplant centers. MP of kidneys from deceased donors has been increasingly adopted by many centers even though clinical and cost effectiveness studies remain uncertain in the United States. Between 2012 and 2014, out of 31,798 kidneys available for transplant, 11,998 (38%) of them were machine perfused. Over the same three-year period, the number of kidneys pumped annually increased by over 20%. This is an opportune time to investigate the effectiveness of MP compared to mild hypothermia, as there are enough OPOs currently using MP that if mild hypothermia was found to be a non-inferior intervention, there would be considerable cost savings. Similarly, over 60% of kidneys do not receive machine perfusion and findings that demonstrates a benefit of machine perfusion would likely lead to rapid increase in use. In addition, DGF still occurs in up to 56% of high-risk kidneys despite using one of these protective measures and their combined use may be the best approach moving forward. Either way, a new evidence-based standard will be created that will significantly affect the way kidney transplants are handled. METHODS: This will be a pragmatic multi-site randomized controlled trial that bases enrollment on each OPO/Donation Service Area's current pumping criteria. There will be two main groups of DNDDs, 1. those that are "pump eligible" based on current practice (this group typically resembles traditional expanded criteria donors, but is increased in some areas) and 2. those that are lower risk and whose kidneys do not receive MP ("not pump eligible"). Kidneys from donors who are considered"pump eligible" currently receive MP based on their increased risk for failure. In this trial, "pump eligible" DNDDs will be randomized to one of three groups (1) normothermia (36.5-37.5 C) plus MP of both kidneys (standard of practice control group), (2) mild hypothermia (34-35 C) plus MP of the left kidney only, and (3) mild hypothermia plus MP of the right kidney only. In this manner, the same number of kidneys will be randomized to each of the three treatment strategies (MP alone, mild hypothermia alone, or MP + hypothermia). It is important to note that kidneys from "pump eligible"/higher risk DNDDs will still receive one form of protection and possibly two. In contrast, "not pump eligible" DNDDs will only be randomized to one of two groups: (1) therapeutic mild hypothermia or (2) normothermia. Being that the Mild Hypothermia Trial was stopped early for efficacy in the overall DNDD population, there was insufficient statistical power to confirm a benefit in standard criteria donors (p=0.1 at stoppage). The purpose of this arm of the trial is to validate the protective effect of hypothermia in a larger sample size of lower-risk / "not pump eligible" donors. The following objectives will be addressed by the trial: Determine the non-inferiority of a hypothermia-only strategy to a standard pump-only strategy in high risk DNDDs Evaluate the superiority of a combined hypothermia+MP strategy to both hypothermia or MP alone in high risk DNDDs Evaluate the superiority of mild hypothermia versus standard of care normothermia in lower risk, "not pump eligible" DNDDs Determine the safety of the hypothermia strategy with respect to the function of "bystander"organs (e.g., heart, lung) This protocol has been approved by the OPTN Region 5 Research Committee. In addition, the following steps have been or will be taken: A National communication was sent via TransplantPro to allow for a two-week period for public comment. Only donors whose families and/or advanced directives (donor registry) have authorized research will be included in the study. All organ offers from DNDDs enrolled in the study will include a message in the Donor Highlights section of DonorNet®, a copy of the study summary will be attached to the record, and allocation/transplantation will occur based on standard practice. There will not be any interaction between the study team and the transplant recipients and no additional data will be collected. Recipient graft function data will be derived from standard UNet forms and obtained from the OPTN in a de-identified format.


Recruitment information / eligibility

Status Completed
Enrollment 1427
Est. completion date June 1, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - > 18 years of age, - Brain dead organ donor, - Authorization for research Exclusion Criteria: - Donation after Cardiac Death (DCD) Donor - Coagulopathy, Hemodynamic instability, Electrolyte deficiencies, Pre-existing kidney disease (per study protocol)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pump Eligible - Normothermia - Pump Both Kidneys
Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
Pump Eligible - Hypothermia and Pump Right Kidney
Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage. Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation.
Pump Eligible - Hypothermia and Pump Left Kidney
Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
Not Pump Eligible - Normothermia
Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol
Not Pump Eligible - Hypothermia
Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.

Locations

Country Name City State
United States Southwest Transplant Alliance Dallas Texas
United States Donor Alliance Denver Colorado
United States LifeGift Houston Texas
United States LifeSource Minneapolis Minnesota
United States Donor Network of Arizona Phoenix Arizona
United States Pacific Northwest Transplant Bank Portland Oregon
United States U C San Francisco San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco Oregon Health and Science University

Country where clinical trial is conducted

United States, 

References & Publications (3)

Jochmans I, Watson CJ. Taking the Heat Out of Organ Donation. N Engl J Med. 2015 Jul 30;373(5):477-8. doi: 10.1056/NEJMe1507573. — View Citation

Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, van Kasterop-Kutz M, van der Heide JJ, Squifflet JP, van Heurn E, Kirste GR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009 Jan 1;360(1):7-19. doi: 10.1056/NEJMoa0802289. — View Citation

Niemann CU, Feiner J, Swain S, Bunting S, Friedman M, Crutchfield M, Broglio K, Hirose R, Roberts JP, Malinoski D. Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function. N Engl J Med. 2015 Jul 30;373(5):405-14. doi: 10.1056/NEJMoa1501969. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Delayed Graft Function in Kidney Allografts The incidence of DGF in kidneys from deceased donors enrolled in this trial, obtained from publically available OPTN data. 7 days
Secondary Allograft and Recipient survival for all transplanted organs Allograft and Recipient survival for all transplanted organs from deceased donors enrolled in this trial obtained from publically available OPTN data. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03765814 - The Anticipated Organ Donation Approach
Completed NCT02581111 - Naloxone for Optimizing Hypoxemia Of Lung Donors Phase 2/Phase 3
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT00998972 - N-acetyl-cysteine (NAC) and Kidney Graft Function Phase 3
Completed NCT04528797 - Thyroid and Adrenocortical Hormone Replacement in Organ Donors N/A
Completed NCT03672812 - The Use of Liraglutide in Brain Death Phase 3
Completed NCT04303624 - Understanding Family Refusal
Completed NCT03098706 - Therapeutic Hypothermia in "Expanded Criteria" Brain-dead Donors and Kidney-graft Function N/A
Not yet recruiting NCT04623294 - Online Noninvasive Assessment of Human Brain Death and Deep Coma by Near-infrared Spectroscopy
Recruiting NCT02102945 - Special Imaging Technique to Aid in the Diagnosis of Patients in Coma After Cardiac Arrest N/A
Completed NCT02483273 - Alterations of Conjunctival Microcirculation in Brain Dead Patients N/A
Terminated NCT00675272 - Organ Donation and Hydrocortisone Treatment N/A
Completed NCT03262896 - Neurophysiological Examination in Patients With Brain Death
Not yet recruiting NCT06359119 - Implementation of Apnoea Test for Patients With Suspected Brain Death
Recruiting NCT05202886 - "LiverColor": Machine Learning in Liver Photographs N/A
Completed NCT03281993 - Apnea Tests as the Methods of Brain Death Diagnosis. N/A
Completed NCT03179020 - Donation Network to Optimize Organ Recovery Study N/A
Completed NCT05070182 - Resting Energy Needs in Brain Dead Patients (reSting EneRgy nEeds iN brAin DEad Patients)
Terminated NCT03439995 - Goal of Open Lung Ventilation in Donors N/A
Completed NCT02742857 - Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury Phase 1

External Links